Madrigal May Shake Up NASH Race With Phase II Resolution Data
Madrigal reports data showing that MGL-3196 resolved non-alcoholic steatohepatitis and improved key secondary measures, data that suggest a better effect than other NASH candidates.
You may also be interested in...
Madrigal’s selective THR beta agonist continues to demonstrate hepatic fat-lowering abilities in 36-week data, along with lipid-lowering characteristics. The company hopes to initiate a Phase III study in early 2019.
In a Phase II study, Viking’s VK2809, with the same mechanism as Madrigal’s MGL-3196, shows significant liver fat reduction in NAFLD patients, along with reduction in LDL cholesterol.
Akero is entering the NASH race with a mechanism it thinks will be more powerful than current Phase III candidates and offer better efficacy than two other FGF-targeted candidates now in Phase II.